Beraprost sodium is released as a pharmaceutical-grade active pharmaceutical ingredient for tablet, capsule, granule, and injectable product manufacturing where the approved route of administration permits the specified presentation. The compound is identified by CAS 88475-69-8 and the molecular formula C24H29NaO5, corresponding to a molecular weight of 420.47 g/mol. As a synthetic prostacyclin PGI₂ analogue, beraprost sodium activates IP receptors through adenylate cyclase, producing vasodilation in pulmonary and systemic arterial beds and inhibiting platelet aggregation. The API is manufactured under ICH Q7 requirements, and release documentation includes a certificate of analysis covering identity, assay, related substances, residual solvents, elemental impurities, water content, microbial quality, and particle size distribution where applicable. No single harmonized pharmacopoeial model number exists across all territories; the grade designation is supplier-specific and must be verified against the certificate of analysis and regional marketing authorization requirements.

Which Physicochemical Attributes Define Pharma-Grade Release?

Pharmaceutical-grade certification begins with identity verification by infrared absorption spectrophotometry per Ph. Eur. 2.2.24 and retention-time matching in an HPLC method. The crystalline form is characterized by X-ray powder diffraction because changes in polymorphic form may alter dissolution, bulk density, and blending behavior. Assay for beraprost sodium is normally controlled at 98.0%–102.0% on the anhydrous and solvent-free basis using HPLC with UV detection. Related substance limits follow ICH Q3A(R2) thresholds adapted for a low daily dose; for an API with a maximum daily dose below 1 mg, reporting thresholds at or below 0.05% and qualification thresholds at or below 0.10% are commonly required. Water content determined by Karl Fischer titration per Ph. Eur. 2.5.12 is controlled to ≤1.0% w/w in typical release specifications. Residual solvents are tested by headspace gas chromatography per USP <467> and must satisfy ICH Q3C(R8) option 1 limits. Elemental impurities are measured by ICP-MS per USP <232>/<233>; limits follow ICH Q3D and are assigned according to the intended route of administration.

Blend uniformity for low-dose oral solid dosage forms is dominated by particle size, surface energy, and the number of API particles per single dosage unit. A 20 µg or 40 µg tablet commonly contains beraprost sodium at less than 1% w/w of the total fill mass; therefore the API must be distributed across a sufficient number of particles to avoid content uniformity failures under Ph. Eur. 2.9.40 or USP <905>. Direct compression is used only when the API is micronized or air-jet milled to a controlled particle size distribution and combined with a diluent such as lactose monohydrate or microcrystalline cellulose. Wet granulation may be preferred when the API is sensitive to segregation; however, the granulation fluid composition must avoid high pH and prolonged heat exposure because prostacyclin analogues can undergo hydrolysis. Capsule filling with low-fill-weight dosator equipment requires sufficient flow after addition of glidants such as colloidal silicon dioxide; granule formulations are typically filled using tamping-pin or dosator systems with fill weight control at ±3% or tighter.

For low-dose direct compression, a powder blend with bulk density between 0.40 g/mL and 0.65 g/mL and a Carr index ≤25% is generally required to reduce segregation risk. Short blending times and stepwise geometric dilution are used because beraprost sodium at microgram scale can segregate or adhere to vessel walls. The API is commonly pre-blended with a portion of filler before final blending; bin blending with an intensifier bar is typical, while prolonged low-shear blending may generate electrostatic charge. Static dissipation via grounding or ionizing bars is recommended when relative humidity is below 40%. Tablet compression on rotary presses using B-tooling and multi-tip punches may be controlled by compression force and tablet weight feedback; typical direct compression of microcrystalline cellulose/lactose blends operates at compression forces between 5 kN and 15 kN and produces tablet hardness above 5 kp. Dissolution testing follows USP <711> with Apparatus 2 paddle at 50 rpm or Apparatus 1 basket at 100 rpm, depending on the regional monograph and the formulation design.

Cleaning validation for beraprost sodium requires an analytical limit of quantification below the health-based exposure limit. If a permitted daily exposure is set at 0.5 µg/day based on pharmacological potency, swab and rinse limits are calculated from equipment surface area, batch size, and subsequent product daily dose. Visible residue limits alone are insufficient; HPLC or LC-MS/MS with a LOQ below 0.01 µg/mL is commonly required. Published data for this specific API’s permitted daily exposure are limited; final cleaning limits must be justified in the site’s quality risk assessment and regional regulatory file.

Injectable-Grade Requirements for a Prostacyclin Analogue

Parenteral presentations of beraprost sodium require additional release and processing controls beyond those applied to oral solid dosage forms. Bacterial endotoxins are measured by Limulus amebocyte lysate assay per Ph. Eur. 2.6.14 or USP <85>, with the lot limit calculated from the maximum intended dose and route of administration; the general intravenous threshold is 5 EU/kg/h, while intrathecal products require 0.2 EU/kg/h. Injectable-grade API is additionally controlled for bioburden per Ph. Eur. 2.6.12/2.6.13, particulate matter per Ph. Eur. 2.9.19 or USP <788>, and container closure integrity per USP <1207>. Aqueous solutions of prostacyclin analogues are prone to hydrolytic and oxidative degradation; therefore formulation under nitrogen, pH buffering, and light protection during filtration and filling are required. Lyophilized presentations require a collapse temperature below the shelf temperature during primary drying; residual moisture after lyophilization is generally specified at ≤1.0% w/w but must be justified by stability data. Sterile filtration through 0.22 µm PVDF or PES filters is used because terminal autoclaving may degrade the prostacyclin ring. Published data for beraprost sodium injection are more limited than for oral presentations; each injectable formulation must be qualified through forced-degradation studies under ICH Q1A(R2).

Prostacyclin Analogue Differentiation Across Route, Stability, and Dosing Interval

Beraprost sodium differs from epoprostenol sodium, treprostinil sodium, and iloprost in chemical stability, administration route, and elimination half-life. Epoprostenol is naturally occurring prostacyclin with a reported elimination half-life of 2–3 minutes; it requires continuous intravenous infusion through a central venous catheter and is formulated as an alkaline lyophilized powder because of rapid hydrolysis at neutral pH. Treprostinil is a tricyclic benzindene analogue with a half-life of approximately 4 hours, permitting subcutaneous, intravenous, inhaled, and oral dosing. Iloprost is a carbacyclin analogue with a half-life of 20–30 minutes, delivered by intermittent inhalation or intravenous infusion. Beraprost sodium is an orally available benzoprostacyclin analogue with a reported elimination half-life of approximately 1 hour, which necessitates multiple daily oral doses but avoids continuous infusion or inhalation hardware. This difference is the primary operational distinction in manufacturing site selection: oral solid dose equipment is not required for epoprostenol or iloprost inhalation products, while beraprost sodium can be processed on conventional tablet and capsule lines.

Residual solvent testing for beraprost sodium should include process-specific solvents from the final synthetic steps. If the route uses palladium-catalysed hydrogenation or coupling, the elemental impurities profile must demonstrate compliance with ICH Q3D for the relevant route; default parenteral limits for palladium and platinum are 10 µg/g, while oral limits are generally 100 µg/g. The API should be stored in tightly closed, light-resistant containers under nitrogen; relative humidity above 60% during dispensing may require desiccated handling because the sodium salt form can adsorb moisture and affect assay or water content. The API should not be combined with strongly alkaline excipients in aqueous granulation, because pH above 8.0 accelerates ester and prostacyclin ring hydrolysis. Oxidizing agents and transition-metal ions should be excluded from the formulation; if a metal oxide colorant is required, compatibility under ICH Q1A(R2) stress conditions must be established. Processing temperatures above 60 °C during drying or hot-melt extrusion are not recommended unless forced-degradation data demonstrate recoveries above 95% without new impurities above ICH Q3B qualification thresholds. For oral solid dosage, packaging with aluminium-aluminium blisters or HDPE bottles with desiccant is used to protect against moisture and light; the specific retest period is assigned from long-term stability data according to ICH Q1A(R2).